Statistical and practical considerations for clinical evaluation of predictive biomarkers

Mei Yin C. Polley; Boris Freidlin; Edward L. Korn; Barbara A. Conley; Jeffrey S. Abrams; Lisa M. McShane

doi:10.1093/jnci/djt282

Statistical and practical considerations for clinical evaluation of predictive biomarkers

Mei Yin C. Polley, Boris Freidlin, Edward L. Korn, Barbara A. Conley, Jeffrey S. Abrams, Lisa M. McShane

Quantitative Health Sciences

Research output: Contribution to journal › Review article › peer-review

89 Scopus citations

Abstract

Predictive biomarkers to guide therapy for cancer patients are a cornerstone of precision medicine. Discussed herein are considerations regarding the design and interpretation of such predictive biomarker studies. These considerations are important for both planning and interpreting prospective studies and for using specimens collected from completed randomized clinical trials. Specific issues addressed are differentiation between qualitative and quantitative predictive effects, challenges due to sample size requirements for predictive biomarker assessment, and consideration of additional factors relevant to clinical utility assessment, such as toxicity and cost of new therapies as well as costs and potential morbidities associated with routine use of biomarker-based tests.

Original language	English (US)
Pages (from-to)	1677-1683
Number of pages	7
Journal	Journal of the National Cancer Institute
Volume	105
Issue number	22
DOIs	https://doi.org/10.1093/jnci/djt282
State	Published - Nov 20 2013

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1093/jnci/djt282

Cite this

@article{c2ffd9465aea4cf28c5a502c031fb680,

title = "Statistical and practical considerations for clinical evaluation of predictive biomarkers",

abstract = "Predictive biomarkers to guide therapy for cancer patients are a cornerstone of precision medicine. Discussed herein are considerations regarding the design and interpretation of such predictive biomarker studies. These considerations are important for both planning and interpreting prospective studies and for using specimens collected from completed randomized clinical trials. Specific issues addressed are differentiation between qualitative and quantitative predictive effects, challenges due to sample size requirements for predictive biomarker assessment, and consideration of additional factors relevant to clinical utility assessment, such as toxicity and cost of new therapies as well as costs and potential morbidities associated with routine use of biomarker-based tests.",

author = "Polley, {Mei Yin C.} and Boris Freidlin and Korn, {Edward L.} and Conley, {Barbara A.} and Abrams, {Jeffrey S.} and McShane, {Lisa M.}",

year = "2013",

month = nov,

day = "20",

doi = "10.1093/jnci/djt282",

language = "English (US)",

volume = "105",

pages = "1677--1683",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "22",

}

TY - JOUR

T1 - Statistical and practical considerations for clinical evaluation of predictive biomarkers

AU - Polley, Mei Yin C.

AU - Freidlin, Boris

AU - Korn, Edward L.

AU - Conley, Barbara A.

AU - Abrams, Jeffrey S.

AU - McShane, Lisa M.

PY - 2013/11/20

Y1 - 2013/11/20

N2 - Predictive biomarkers to guide therapy for cancer patients are a cornerstone of precision medicine. Discussed herein are considerations regarding the design and interpretation of such predictive biomarker studies. These considerations are important for both planning and interpreting prospective studies and for using specimens collected from completed randomized clinical trials. Specific issues addressed are differentiation between qualitative and quantitative predictive effects, challenges due to sample size requirements for predictive biomarker assessment, and consideration of additional factors relevant to clinical utility assessment, such as toxicity and cost of new therapies as well as costs and potential morbidities associated with routine use of biomarker-based tests.

AB - Predictive biomarkers to guide therapy for cancer patients are a cornerstone of precision medicine. Discussed herein are considerations regarding the design and interpretation of such predictive biomarker studies. These considerations are important for both planning and interpreting prospective studies and for using specimens collected from completed randomized clinical trials. Specific issues addressed are differentiation between qualitative and quantitative predictive effects, challenges due to sample size requirements for predictive biomarker assessment, and consideration of additional factors relevant to clinical utility assessment, such as toxicity and cost of new therapies as well as costs and potential morbidities associated with routine use of biomarker-based tests.

UR - http://www.scopus.com/inward/record.url?scp=84890541361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890541361&partnerID=8YFLogxK

U2 - 10.1093/jnci/djt282

DO - 10.1093/jnci/djt282

M3 - Review article

C2 - 24136891

AN - SCOPUS:84890541361

SN - 0027-8874

VL - 105

SP - 1677

EP - 1683

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

IS - 22

ER -

Statistical and practical considerations for clinical evaluation of predictive biomarkers

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this